The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies

Cited by (211)

Items 101–200 of 211

1. Two antibodies show broad, synergistic neutralization against SARS-CoV-2 variants by inducing conformational change within the RBD
   Hui Sun, Tingting Deng, Yali Zhang, Yanling Lin, Yanan Jiang, Yichao Jiang, Yang Huang, Shuo Song, Lingyan Cui, Tingting Li et al. · 2023 · Protein & Cell
2. Emergence of SARS-CoV-2 with Dual-Drug Resistant Mutations During a Long-Term Infection in a Kidney Transplant Recipient
   Yoko Tanino, Keisuke Nishioka, Chie Yamamoto, Yohei Watanabe, Tomo Daidoji, Masataka Kawamoto, Sayaka Uda, Shoko Kirito, Yuta Nakagawa, Yu Kasamatsu et al. · 2024 · Infection and Drug Resistance
3. A cryptic site in class 5 epitope of SARS-CoV-2 RBD maintains highly conservation across natural isolates
   Lingyan Cui, Tingting Li, Miaolin Lan, Ming Zhou, Wenhui Xue, Sibo Zhang, Hong Wang, Minqing Hong, Yali Zhang, Lunzhi Yuan et al. · 2024 · iScience
4. TDP43 aggregation at ER-exit sites impairs ER-to-Golgi transport
   Hongyi Wu, Loo Chien Wang, Belle Miaoer Sow, Damien Meng-Kiat Leow, Jin Zhu, Kathryn M. Gallo, Kathleen Wilsbach, Roshni Gupta, Lyle W. Ostrow, Crystal Jing Jing Yeo et al. · 2024 · Nature Communications
5. Regen-Cov ® Antibody Cocktail Bioanalytical Strategy: Comparison of Lc-Mrm-Ms and Immunoassay Methods for Drug Quantification
   Susan C. Irvin, Samit Ganguly, Rachel Weiss, Chinnasamy Elango, Xuefei Zhong, Yuan Mao, Hong Yan, Ning Li, Giane Sumner, Kenneth C. Turner et al. · 2021 · Bioanalysis
6. IMM-BCP-01, a patient-derived anti–SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2
   Pavel A. Nikitin, Jillian M. DiMuzio, John P. Dowling, Nirja B. Patel, Jamie L. Bingaman, Baron C. Heimbach, Noeleya Henriquez, Chris Nicolescu, Antonio M Polley, Eden L. Sikorski et al. · 2022 · Science Immunology
7. Corticosteroids: A boon or bane for COVID-19 patients?
   Subhadeep Sen, Bhagat Singh, Goutam K. Biswas · 2022 · Steroids
8. Clinical manifestations of COVID-19 infection in dialysis patients and protective effect of COVID-19 vaccine
   Xuehan Zhang, Qingfeng Chen, Gaosi Xu · 2023 · Inflammation Research
9. SARS-CoV-2 antibodies from children exhibit broad neutralization and belong to adult public clonotypes
   Steven C. Wall, Naveenchandra Suryadevara, Changil Kim, Andrea R. Shiakolas, Clinton Holt, Emma B. Irbe, Perry T. Wasdin, Yukthi P. Suresh, Elad Binshtein, Elaine C. Chen et al. · 2023 · Cell Reports Medicine
10. Monoclonal Antibodies as Potential COVID-19 Therapeutic Agents
    Jacek Plichta, Piotr Kuna, Michał Panek · 2022 · COVID
11. A high-throughput, automated, cell-free expression and screening platform for antibody discovery
    Andrew C. Hunt, Bastian Vögeli, Weston Kightlinger, Danielle J. Yoesep, Antje Krüger, Michael C. Jewett · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
12. Integrating artificial intelligence-based epitope prediction in a SARS-CoV-2 antibody discovery pipeline: caution is warranted
    Delphine Diana Acar, Wojciech Witkowski, Magdalena Wejda, Ruifang Wei, Tim Desmet, Bert Schepens, Sieglinde De Cae, Koen Sedeyn, Hannah Eeckhaut, Daria Fijałkowska et al. · 2024 · EBioMedicine
13. Estimated Health Outcomes and Costs of COVID-19 Prophylaxis With Monoclonal Antibodies Among Unvaccinated Household Contacts in the US
    Abraham D. Flaxman, Rodal S. Issema, Ruanne V. Barnabas, Jennifer M. Ross · 2022 · JAMA Network Open
14. Serosurvey in SARS‐CoV‐2 inactivated vaccine‐elicited neutralizing antibodies against authentic SARS‐CoV‐2 and its viral variants
    Lirong Zou, Huan Zhang, Zhonghua Zheng, Yushan Jiang, Yushi Huang, Shujian Lin, Jianxiang Yu, Xiaoling Deng, Jianfeng He, Chenguang Shen et al. · 2022 · Journal of Medical Virology
15. Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody JS016 in Hospitalized Chinese Patients with COVID-19: a Phase 2/3, Multicenter, Randomized, Open-Label, Controlled Trial
    Run Dong, Li Jiang, Ting Yang, Changsong Wang, Yi Zhang, Xu Chen, Jianfeng Xie, Yuanbin Guo, Li Weng, Yan Ming Kang et al. · 2022 · Antimicrobial Agents and Chemotherapy
16. The Activin/FLRG Pathway Associates with Poor COVID-19 Outcomes in Hospitalized Patients
    Megan McAleavy, Qian Zhang, Peter J. Ehmann, Jianing Xu, Matthew F. Wipperman, Dharani K. Ajithdoss, Pan Li, Matthew Wakai, Raphael Simonson, Abhilash Gadi et al. · 2021 · Molecular and Cellular Biology
17. Impact of Casirivimab-Imdevimab on Severe Acute Respiratory Syndrome Coronavirus 2 Delta Variant Nasopharyngeal Virus Load and Spike Quasispecies
    Camille Vellas, Arnaud Del Bello, Géraldine Gaube, Pauline Trémeaux, Nicolas Jeanne, Noémie Ranger, Guillaume Martin‐Blondel, Pierre Delobel, Nassim Kamar, Jacques Izopet · 2022 · Open Forum Infectious Diseases
18. A comprehensive review on immunogen and immune-response proteins of SARS-CoV-2 and their applications in prevention, diagnosis, and treatment of COVID-19
    Daohong Zhang, Deepak Kukkar, Ki‐Hyun Kim, Poornima Bhatt · 2024 · International Journal of Biological Macromolecules
19. Impact of mAb-FcRn affinity on IgG transcytosis across human well-differentiated airway epithelium
    Kohei Togami, Whitney Wolf, Lucas C. Olson, Madison Card, Limei Shen, Alison Schaefer, Kenichi Okuda, Larry Zeitlin, Michael H. Pauly, Kevin J. Whaley et al. · 2024 · Frontiers in Immunology
20. Monoclonal antibodies against the spike protein alter the endogenous humoral response to SARS-CoV-2 vaccination and infection
    Christopher D. Petro, Andrea T. Hooper, Avery Peace, Kusha A Mohammadi, Will Eagan, Sayda M. Elbashir, Anthony T. DiPiazza, Daniel L. Makrinos, Kristen E. Pascal, Pooja Bandawane et al. · 2024 · Science Translational Medicine
21. Passive Immunization in the Prevention and Treatment of Viral Infections
    Romila Moirangthem, Yotam Bar‐On · 2025 · European Journal of Immunology
22. Spike Protein Genetic Evolution in Patients at High Risk of Severe Coronavirus Disease 2019 Treated by Monoclonal Antibodies
    Valentin Leducq, Karen Zafilaza, Antoine Fauchois, Emna Ghidaoui, Sophie Sayon, Céline Dorival, Marie-Laure Meledje, Clovis Lusivika‐Nzinga, Youri Yordanov, Guillaume Martin‐Blondel et al. · 2023 · The Journal of Infectious Diseases
23. Antiviral therapy for COVID-19 virus: A narrative review and bibliometric analysis
    Saeid Mezail Mawazi, Nousheen Fathima, Syed Mahmood, Sinan Mohammed Abdullah Al-Mahmood · 2024 · The American Journal of Emergency Medicine
24. Phase 2 dose-ranging study of the virologic efficacy and safety of the combination COVID-19 antibodies casirivimab and imdevimab in the outpatient setting
    Cynthia Portal‐Celhay, Eduardo Forleo‐Neto, Will Eagan, Bret J. Musser, John D. Davis, Kenneth C. Turner, Thomas D. Norton, Andrea T. Hooper, Jennifer D. Hamilton, Cynthia Pan et al. · 2021 · medRxiv
25. A Potent Recombinant Polyclonal Antibody Therapeutic for Protection Against New Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern
    Nicholas P. Wayham, Ariel R. Niedecken, Jan Fredrik Simons, Yao Chiang, Angélica V. Medina‐Cucurella, Rena A. Mizrahi, Ellen K. Wagner, Ashley Gras, Ilana Segal, Peyton Witte et al. · 2023 · The Journal of Infectious Diseases
26. Resistance Analysis Following Sotrovimab Treatment in Participants with COVID-19 During the Phase III COMET-ICE Study
    Sambhavi Subramanian, Gretja Schnell, Julia di Iulio, Anil Kumar Gupta, Adrienne E. Shapiro, Elias H. Sarkis, Amanda Lopuski, Amanda Peppercorn, Melissa Aldinger, Christy M. Hebner et al. · 2023 · Future Virology
27. Structural insights into immune escape at killer T cell epitope by SARS-CoV-2 Spike Y453F variants
    Shasha Deng, Zhihao Xu, Meihua Wang, Jing Hu, Zhuan Liu, Fang Zhu, Peiyi Zheng, Arnaud John Kombe Kombe, Hongliang Zhang, Songquan Wu et al. · 2024 · Journal of Biological Chemistry
28. Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants
    Mikako Ueno, Naoko Iwata‐Yoshikawa, Akihiro Matsunaga, Tadashi Okamura, Sho Saito, Shinobu Ashida, Isao Yoshida, Mami Nagashima, Hiroyuki Asakura, Yu Yaoita et al. · 2022 · Antiviral Research
29. Immune-based therapeutic approaches in COVID-19
    Aysan Moeinafshar, Niloufar Yazdanpanah, Nima Rezaei · 2022 · Biomedicine & Pharmacotherapy
30. Isolation and comparative analysis of antibodies that broadly neutralize sarbecoviruses
    Lihong Liu, Sho Iketani, Yicheng Guo, Ryan G. Casner, Eswar R. Reddem, Manoj S. Nair, Jian Yu, Jasper Fuk‐Woo Chan, Maple Wang, Gabriele Cerutti et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
31. Structural insight into broadening SARS-CoV-2 neutralization by an antibody cocktail harbouring both NTD and RBD potent antibodies
    Wenling Jiang, Yanan Jiang, Hui Sun, Tingting Deng, Kunyu Yu, Qianjiao Fang, Huimin Ge, Miaoling Lan, Yanling Lin, Zhongyue Fang et al. · 2024 · Emerging Microbes & Infections
32. Preparation and characterization of mouse-derived monoclonal antibodies against the hemagglutinin of the H1N1 influenza virus
    Xiantian Lin, Fan Yang, Sijing Yan, Han‐Chung Wu, Ping Wang, Yuxi Zhao, Danrong Shi, Hangping Yao, Haibo Wu, Lanjuan Li · 2024 · Virus Research
33. Engineered DNA-encoded monoclonal antibodies targeting Plasmodium falciparum circumsporozoite protein confer single dose protection in a murine malaria challenge model
    Nicholas J. Tursi, Sophia M. Reeder, Yevel Flores-García, Mamadou A. Bah, Shamika Mathis-Torres, Berenice Salgado-Jimenez, Rianne N. Esquivel, Ziyang Xu, Jacqueline D. Chu, Laurent M. P. F. Humeau et al. · 2022 · Scientific Reports
34. SARS-CoV-2 Mutations, Diagnosis and Their Concern
    Yakup Artik, Nevra Pelin Cesur, Nelisa Türkoğlu Laçin · 2022 · Archives of Molecular Biology and Genetics
35. Convergent evolution in SARS-CoV-2 Spike creates a variant soup that causes new COVID-19 waves
    Daniele Focosi, Rodrigo Quiroga, Scott A. McConnell, Marc C. Johnson, Arturo Casadevall · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
36. Native SEC and Reversed-Phase LC–MS Reveal Impact of Fab Glycosylation of Anti-SARS-COV-2 Antibodies on Binding to the Receptor Binding Domain
    Daniel W. Woodall, Christy A. Thomson, Thomas M. Dillon, Arnold McAuley, Lydia B. Green, Ian N. Foltz, Pavel V. Bondarenko · 2023 · Analytical Chemistry
37. Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall
    Marco Tuccori, Irma Convertino, Sara Ferraro, Emiliano Cappello, Giulia Valdiserra, Giulia de Luca, Massimo Franchini, Daniele Focosi · 2022 · Expert Opinion on Drug Discovery
38. Recombinant Decoy Exhibits Broad Protection against Omicron and Resistance Potential to Future Variants
    Haoneng Tang, Yong Ke, Lei Wang, Mingyuan Wu, Tao Sun, Jianwei Zhu · 2022 · Pharmaceuticals
39. Blood‐derived product therapies for SARS‐CoV‐2 infection and long COVID
    Junzheng Wu, Huichuan Yang, Ding Yu, Xiaoming Yang · 2023 · MedComm
40. Genome-first detection of emerging resistance to novel therapeutic agents for SARS-CoV-2
    Manon Ragonnet‐Cronin, Rungtiwa Nutalai, Jiandong Huo, Aiste Dijokaite-Guraliuc, Raksha Das, Aekkachai Tuekprakhon, Piyada Supasa, Chang Liu, Muneeswaran Selvaraj, Natalie Groves et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
41. Lessons learned and implications of early therapies for coronavirus disease in a territorial service center in the Calabria region
    Vincenzo Scaglione, Salvatore Rotundo, Nadia Marascio, Carmela De Marco, Rosaria Lionello, Claudia Veneziano, Lavinia Berardelli, Angela Quirino, Vincenzo Olivadese, Francesca Serapide et al. · 2022 · Research Square
42. A highly potent and broadly accessible bispecific nanobody for the treatment of ebola virus infections
    Fan Bu, Gang Ye, Kimberly M. Morsheimer, Hailey Turner‐Hubbard, Brett Eaton, Manu Anantpadma, Khaggeswar Bheemanapally, Chalet Tan, Robert A. Davey, Fang Li · 2026 · PLoS Pathogens
43. A highly potent nanobody-based bispecific therapeutic provides broad-spectrum protection against ebolavirus
    Meihua Wang, Xinghai Zhang, Wujian Li, Yanfeng Yao, Entao Li, Baoyue Zhang, Jinge Zhou, Shunli Liu, Yongxiang Gao, Zhongliang Zhu et al. · 2026 · Nature Communications
44. XA-Novo: high-throughput mass spectrometry-based de novo sequencing technology for monoclonal antibodies and antibody mixtures
    Yueting Xiong, Wenbin Jiang, Jin Xiao, Qingfang Bu, Jingyi Wang, Zhenjian Jiang, Ling Luo, Xiaoqing Chen, Yijie Qiu, Yangtao Wu et al. · 2026 · Nature Communications
45. A Novel Monoclonal Antibody 1D2 That Broadly Inhibits Clinically Important Aspergillus Species
    Xihua Lian, Amy Scott-Thomas, John G. Lewis, Madhav Bhatia, Stephen T. Chambers · 2022 · Journal of Fungi
46. Casirivimab/imdevimab treatment for outpatient COVID-19 during a SARS-CoV-2 B1.617.2 (Delta) surge at a community hospital
    Erika A. Keshishian, Elizabeth Kuge, Jordan Memmott, Phillip Hasenbalg, Nakiya Belford, Alexander Matlock, Sarah Schritter, Geovar Agbayani, Tyson Dietrich, Anthony Santarelli et al. · 2022 · Journal of Osteopathic Medicine
47. Development of therapeutic antibodies for the treatment of infection diseases and future aspect
    Kenta Haraya, Keisuke Gotanda, Rie Shiokawa, Maiko Hoshino, Chiyomi Kubo, Taichi Kuramochi · 2022 · Drug Delivery System
48. A dual-targeting approach using a human bispecific antibody against the receptor-binding domain of the Middle East Respiratory Syndrome Coronavirus
    Ji Hyun Lee, Ji Woong Kim, Hee Eon Lee, Jin Young Song, Ah Hyun Cho, Jae Hyeon Hwang, Kyun Heo, Sukmook Lee · 2024 · Virus Research
49. Novel Trispecific Neutralizing Antibodies With Enhanced Potency and Breadth Against Pan‐Sarbecoviruses
    Rui Qiao, Yuanchen Liu, Qiyu Mao, Jiayan Li, Yinying Lu, Jialu Shi, Chen Li, Jizhen Yu, Jiami Gong, Xun Wang et al. · 2025 · MedComm
50. Humoral immune response to authentic circulating severe acute respiratory syndrome coronavirus 2 variants elicited by booster vaccination with distinct receptor‐binding domain subunits in mice
    Yushan Jiang, Huan Zhang, Jianhai Yu, Dong Huang, Linlin Zhai, Mengjun Li, Yuelin Wang, Zuning Ren, Lirong Zou, Zhonghua Zheng et al. · 2022 · Journal of Medical Virology
51. Editorial: Post-Exposure Prophylactic Neutralizing Monoclonal Antibodies to SARS-CoV-2 for Individuals at High Risk for COVID-19
    Dinah V. Parums · 2021 · Medical Science Monitor
52. Investigating the evolutionary dynamics and mutational pattern of SARS-CoV-2 spike gene on selected SARS-CoV-2 variants
    Bachir Balech, Alessandra Lo Presti, Claudia Telegrafo, Lucia Maisto, Emanuela Giombini, Angela Di Martino, Luigina Ambrosio, Apollonia Tullo, Paola Stefanelli · 2025 · PLoS ONE
53. The Cellular Characterization of SARS-CoV-2 Spike Protein in Virus-Infected Cells Using the Receptor Binding Domain Binding Specific Human Monoclonal Antibodies
    Conrad En-Zuo Chan, Ching-Ging Ng, Angeline Pei-Chew Lim, Shirley G. K. Seah, De Hoe Chye, Steven K. K. Wong, Jie-Hui Lim, Vanessa Zi-Yun Lim, Soak-Kuan Lai, Pui-San Wong et al. · 2022 · Journal of Virology
54. Variations from SARS-CoV-2 to Omicron: A new threat knocking at world's door
    Acharya Balkrishna, Akansha Rohela, Ashwani Kumar, AcVedpriya Arya, Nazam Khan · 2022 · Journal of Applied Pharmaceutical Science
55. Neutralizing breadth of antibodies targeting diverse conserved epitopes between SARS-CoV and SARS-CoV-2
    Hualong Xiong, Hui Sun, Siling Wang, Lunzhi Yuan, Liqin Liu, Yuhe Zhu, Jinlei Zhang, Yang Huang, Ruoyao Qi, Yao Jiang et al. · 2022 · Research Square
56. Scalable Production of Recombinant Vesicular Stomatitis Virus Pseudoparticles Using HEK293 Suspension Cultures
    Zhe Zhang, Elzbieta H Wloga, Benjamin O. Fulton, Louis Coplan, Hanne Bak, Andrew D. Tustian · 2025 · Biotechnology and Bioengineering
57. Analytical strategies for identification and quantitation of heterodimers in co-formulated monoclonal antibody cocktails by native SEC-MS
    Wenjing Peng, Yuetian Yan, Victoria C. Cotham, Andrew J. Heindel, Shunhai Wang, Ning Li · 2025 · Scientific Reports
58. Identification and characterization of a SARS-CoV-2 M pro G23 deletion ensitrelvir-resistant mutant
    Yao Ma, Chengjin Ye, R Rahisuddin, Sara Hussein Mahmoud, Anastasija Čupić, Ahmed Magdy Khalil, Esteban Castro, Nathaniel D. Jackson, Mahmoud Bayoumi, Shailee Arya et al. · 2026 · mBio
59. A SARS-CoV-2 neutralizing antibody discovery by single cell sequencing and molecular modeling
    Zheyue Wang, Qi Tang, Bende Liu, Wenqing Zhang, Yufeng Chen, Ningfei Ji, Peng Yan, Xiaohui Yang, Daixun Cui, Weiyu Kong et al. · 2022 · Journal of Biomedical Research
60. The anti-SARS-CoV-2 effect and mechanism of Chiehyuan herbal oral protection solution
    Ching-Yuan Wu, Yao-Hsu Yang, Yu-Shih Lin, Li-Hsin Shu, Yu-Ching Cheng, Hung-Te Liu, Yinni Lin, I-Yun Lee, Wei-Tai Shih, Pei-Rung Yang et al. · 2023 · Heliyon
61. Magnetic Enrichment of SARS-CoV-2 Antigen-Binding B Cells for Analysis of Transcriptome and Antibody Repertoire
    Maureen Banach, Isaac T. W. Harley, Mary K. McCarthy, Cody Rester, Adonis Stassinopoulos, Ross M. Kedl, Thomas E. Morrison, John C. Cambier · 2022 · Magnetochemistry
62. Assessment of unvaccinated and vaccinated patients with coronavirus disease 2019 (COVID-19) treated with monoclonal antibodies during the delta wave (July 1–August 20, 2021): a retrospective observational monocentric study
    Yi Guo, Kelsie Cowman, Mei H. Chang, Hongkai Bao, Austin Golia, Terrence D McSweeney, Linda Bard, Roxanne Simpson, Erin Andrews, Liise‐anne Pirofski et al. · 2022 · BMC Infectious Diseases
63. Doubtful clinical benefit of casirivimab-imdevimab treatment for disease severity outcome of high-risk patients with SARS-CoV-2 delta variant infection
    Noaa Shopen, Michal Dekel, Michal Mizrahi, Efrat Zandberg, Nancy Bishouty, Daniel Talmud, Ben Vaknin, Shira Haberman, Malka Katz Shalhav, David Zeltser et al. · 2022 · European Journal of Internal Medicine
64. Neutralizing monoclonal antibodies against SARS-CoV-2 for COVID-19 pneumonia in a rituximab treated patient with systemic sclerosis—A case report and literature review
    Melek Yalçın Mutlu, Jule Taubmann, Jochen Wacker, Koray Taşçılar, Filippo Fagni, Maximilian Gerner, Daniel Klett, Georg Andreas Schett, Bernhard Manger, David Simón · 2022 · Frontiers in Medicine
65. Functional and structural characterization of a combination of pan-sarbecovirus antibodies with potent antiviral activity
    Grace Marden, Kimberly P. Schmitt, Maxwell I. Zimmerman, Alex H. Ramos, Monica Menzenski, Geetika Sharma, Hongru Li, Eric Carlin, Anne M. Jecrois, Claudio L. Morales-Pérez et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
66. Monoclonal antibodies: their place in applied medicine and their role in the newest infectious disease – history, present, and future. Literature review
    Petar Yordanov Atanasov, Maria Georgieva Moneva-Sakelarieva, Yozlem Ali Kobakova, Stefka Achkova Ivanova, Maria Stamova Vakrilova Becheva, Angelina Georgieva Kirkova-Bogdanova, Maria Sevdelinova Chaneva, Ventseslava Petrova Atanasova, Radoslav Fedeev Todorov, Nikolay Zarkov Bashev et al. · 2025 · Pharmacia
67. Development of ACE2-tropic-betacoronavirus therapeutics for future pandemic preparedness
    Ashley Utz, Matt Armbrust, Thuy‐Tien T. Nguyen, Mary Kate Morris, Chris O. Matthews, Pallavi Kompella, Zheng Cao, Ji Won Ha, Arvie Violette, R. Camille Brewer et al. · 2025 · Nature Communications
68. Re-infection with SARS-CoV-2 is associated with increased antibody breadth and potency against diverse sarbecovirus strains
    Michelle Lilly, Felicitas Ruiz, William B. Foreman, Vrasha Chohan, Jamie Guenthoer, Delphine Depierreux, Viren A. Baharani, Duncan Ralph, Alex Harteloo, Helen Y. Chu et al. · 2026 · mBio
69. Potent in vitro synergistic antiviral effects of the pan-coronavirus fusion inhibitor EK1 in combination with RBD-specific antibodies or M pro inhibitors
    Ruixue Xiu, Yuanzhou Wang, Wenbo Cai, Qian Wang, Minxiang Xie, Yingdan Wang, Cheng Li, Qiao Wang, Jinghe Huang, Tianlei Ying et al. · 2026 · Journal of Virology
70. A cocktail of SARS-CoV-2 S stem helix domain and receptor binding domain human monoclonal antibodies prevents the emergence of viral escape mutants
    Yao Ma, Chengjin Ye, Michael S. Piepenbrink, Sara Hussein Mahmoud, Anastasija Čupić, Esteban Castro, Nathaniel D. Jackson, Mahmoud Bayoumi, Alvaro Souto Padron, Adolfo García‐Sastre et al. · 2026 · Microbiology Spectrum
71. Low frequency variants can predetermine antiviral drug resistance development in herpes simplex virus type 1
    Lena Jaki, Florian Full, Udo Gieraths, Valeria Falcone, Zsolt Ruzsics, Hartmut Hengel, Marcus Panning, Jonas Fuchs · 2026 · PLoS Pathogens
72. Noninferiority of Subcutaneous Versus Intravenous Casirivimab/Imdevimab for Outpatient Treatment of SARS-CoV-2 in a Real-World Setting
    Alex Belote, Sharon Reece, Samantha Robinson, Hanna Jensen, Sheena W. CarlLee, Megan Clark, Spencer Parnell, Caroline G. Geels, James Newton · 2022 · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
73. Use of Casirivimab and Imdevimab for the Treatment of COVID-19
    Ryan Liu, Rohan K. Mangal, Thor Shiva Stead, Andrew R Barbera, Latha Ganti · 2022 · Cureus
74. Successful Combination of Remdesivir and Convalescent Plasma to Treat a Patient with Rituximab-Related B-Cell Deficiency and Prolonged COVID-19: A Case Report
    Giorgio Raho, William Cordeddu, Davide Firinu, Stefano Del Giacco, Goffredo Angioni · 2022 · Anti-Infective Agents
75. Precision mapping of the functional epitope of a SARS-CoV-2 neutralizing antibody via hydrogen–deuterium exchange mass spectrometry
    Ji Woong Kim, In Young Ko, Ha Gyeong Shin, Saehae Choi, Ha Rim Yang, Ju Rang Woo, Sukmook Lee · 2025 · Microchemical Journal
76. Public Health Concerns of SARS-CoV-2 Omicron Variant: What We Know So Far!
    Seyi Samson Enitan, Peace Ojonugwa Idris, Emmanuel Ileoma, Nwachi Idume Ogbonna, Oluyemisi Ajike Adekunbi, Grace Eleojo Itodo, Ernest Chibuike Ohanu, Surajudeen Alim Junaid, Effiong Joseph Effiong, Oluwabusolami Oluwatosin Jegede · 2022 · Journal of Virology Research & Reports
77. What Is New in Prophylaxis and Treatment of COVID-19 in Renal Transplant Patients? A Report from an ESOT Meeting on the Topic
    Maurizio Salvadori · 2022 · Transplantology
78. Unique COVID/Anti-Spike Protein Immune Responses in Two Elderly Patients without COVID-19 Vaccination
    2022
79. Endogenous antibody responses in REGN-COV2-treated SARS-CoV-2-infected individuals
    Ashwini Kurshan, Luke B. Snell, Lucie Prior, Jerry C H Tam, Carl Graham, Rajeni Thangarajah, Jonathan D. Edgeworth, Gaia Nebbia, Katie J. Doores · 2023 · Oxford Open Immunology
80. The Efficacy of Recombinant Drugs in COVID-19 Treatment
    Mostafa Norizadeh · 2023 · Advances in Pharmacology & Clinical Trials
81. Preclinical Efficacy of IMM-BCP-01, a Highly Active Patient-Derived Anti-SARS-CoV-2 Antibody Cocktail
    Pavel A. Nikitin, Jillian M. DiMuzio, John P. Dowling, Nirja B. Patel, Jamie L. Bingaman, Baron C. Heimbach, Noeleya Henriquez, Chris Nicolescu, Antonio M Polley, Eden L. Sikorski et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
82. REGEN-COV antibody cocktail (casirivimab/imdevimab) for the treatment of inpatients with early hospital-acquired COVID-19: a single center experience
    Antonio Faraone, Francesca Fabbrizzi, Tommaso Picchioni, Elena Lovicu, Lorenzo Tofani, Giulia Scocchera, Aldo Lo Forte, Andrea Crociani, Paolo Carrai, Serena Sbaragli et al. · 2022 · Research Square
83. The cellular characterisation of SARS-CoV-2 spike protein in virus-infected cells using Receptor Binding Domain-binding specific human monoclonal antibodies
    Conrad En-Zuo Chan, Ching-Ging Ng, Angeline Pei-Chew Lim, Shirley G. K. Seah, De Hoe Chye, Steven K. K. Wong, Jie-Hui Lim, Vanessa Zi-Yun Lim, Soak-Kuan Lai, Pui-San Wong et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
84. Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape
    Fangzhu Zhao, Celina Keating, Gabriel Ozorowski, Namir Shaabani, Irené M. Francino-Urdaniz, Shawn Barman, Oliver Limbo, Alison Burns, Pan-Pan Zhou, Michael J. Ricciardi et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
85. A High-Risk Patient With COVID-19 Vaccine Hesitancy Successfully Treated With Monoclonal Antibodies Through Two Major Surges
    Hitesh Gurjar, Haider Ghazanfar, Asim Haider, Nolberto Hernandez, Abhilasha Jyala, Sridhar S. Chilimuri · 2022 · Cureus
86. Clinical Study of Antibody Cocktail Therapy for COVID-19
    Kazuki Yamada, Satoshi Suzuki, Yoko Tanino, Keiko Suzuki, Takaya Ichikawa, Masahide Nakajima, Akihito Tampo, Shin Kukita, Shohei Kuroda, Akito Uehara et al. · 2022 · Kansenshogaku zasshi
87. Proteomic understanding of SARS-CoV-2 infection and COVID-19: Biological, diagnostic, and therapeutic perspectives
    Fares Al‐Ejeh, Maysaloun Merhi, Mariam Al-Muftah, Queenie Fernandes, Lobna Al-Zaidan, Takwa Bedhiafi, Sarra Mestiri, Dina Moustafa, Nassiba Taib, Varghese Philipose Inchakalody et al. · 2023 · Elsevier eBooks
88. Terapia de REGEN COV como base de terapia inmunomoduladora mixta en pacientes hospitalizados por neumonía por SARS-CoV-2: Serie de casos
    Natalia García, Annette García, Henry Álvarez, Osmayre Ovalle, Nicolle Peña, Katherine Calderón, Anthony Gutiérrez · 2023 · Respirar
89. The development of papain‐like protease from SARS‐CoV‐2, a potential drug target for antiviral screening: A review
    Riswanto Napitupulu, Is Helianti, Maimunah Maimunah, Fairuz Andini Fatiningtyas, Amarila Malik · 2023 · Indonesian Journal of Biotechnology
90. An Initial Experience with Antibody Cocktail CASIRIVIMAB and IMDEVIMAB in a Center of Excellence
    P Amal Johnson, T. Suresh Babu, R Narasimhan · 2021 · Journal of Association of Pulmonologist of Tamil Nadu
91. Engineered Therapeutic Antibody Against SARS-CoV-2
    Monrat Chulanetra · 2023 · Current Clinical Microbiology Reports
92. Evidence that the SARS-CoV-2 S protein undergoes a conformational change at the Golgi Complex that leads to the formation of virus neutralising antibody binding epitopes in the S1 protein subunit.
    Richard Joseph Sugrue, Boon Huan Tan, Soak Kuan Lai, Conrad En-Zuo Chan, Yanjun Wu · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
93. Patient-Reported Outcomes in COVID-19 Treatment with Monoclonal Antibodies Reveal Benefits in Return to Usual Activities
    Diana Rofail, Mohamed A. Hussein, Ulrike Naumann, Anna J. Podolanczuk, Thomas D. Norton, Shazia Ali, Vera Mastey, Cristina Ivanescu, Boaz Hirshberg, Gregory P. Geba · 2024 · Infectious Diseases and Therapy
94. Evidence that the SARS-CoV-2 S protein undergoes a conformational change at the Golgi complex that leads to the formation of virus neutralising antibody binding epitopes in the S1 protein subunit
    Yanjun Wu, Soak Kuan Lai, Conrad En-Zuo Chan, Boon Huan Tan, Richard Joseph Sugrue · 2024 · Virology
95. Simplified and Rapid Workflow Enhances Throughput of De Novo Sequencing of COVID-19 Neutralizing Antibodies
    Yueting Xiong, Xiao Jin, Wenbin Jiang, Jingyi Wang, Qingfang Bu, Xiaoqing Chen, Yangtao Wu, Rongshan Yu, Quan Yuan, Ningshao Xia · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
96. Assessing the safety and pharmacokinetics of casirivimab and imdevimab (CAS+IMD) in a cohort of pregnant outpatients with COVID-19: results from an adaptive, multicentre, randomised, double-blind, phase 1/2/3 study
    Thomas D. Norton, Mazhar Thakur, Samit Ganguly, Shazia Ali, Jesse T. Chao, Alpana Waldron, Jing Xiao, Yogesh Patel, Kenneth C. Turner, John D. Davis et al. · 2024 · BMJ Open
97. Mechanisms of Resistance to Antiviral Agents
    Robert W. Shafer, Guy Boivin, A Howe, Sunwen Chou · 2023 · ClinMicroNow
98. Mechanisms of Resistance to Antiviral Agents
    Robert W. Shafer, Guy Boivin, A Howe, Sunwen Chou · 2023 · ClinMicroNow
99. Treatment of COVID-19 with casirivimab/indevimab in a patient with cervical spine injury: A case report
    Miljana Vrhovac, Tijana Stanišić, Milan Mirković, Jelena Veličković, Sead Dalifi, Danilo Jeremić, Filip Pilipović, Tatjana Adžić‐Vukičević · 2025 · Srpski medicinski casopis Lekarske komore
100. Epitope-driven polyfunctional divergence of SARS-CoV-2 RBD antibodies
     Pierre Rosenbaum, Cyril Planchais, Timothée Bruel, Maxime Beretta, Isabelle Staropoli, William Bolland, Florence Guivel‐Benhassine, Delphine Planas, French COVID Cohort Study Group, CORSER Study Group et al. · 2026 · iScience